Abstract Library

#4609 External validation of Rachel score: A prognostic tool for lung neuroendocrine tumours

Introduction: Lung NETs are a heterogeneous group of tumours with variegated clinical presentation and course. The histological subtype (TC vs AC) and TNM stage are established prognostic factors. In a previous work by our group, we developed a prognostic model named Rachel score, with a satisfactory ability to predict OS and PFS in this population.

Conference:

Presenting Author: La Salvia A

Authors: La Salvia A, Marcozzi B, Lamberti G, Manai C, Mazzilli R,

Keywords: lung neuroendocrine tumour, prognostic tool, Rachel score, external cohort, validation,

#3433 Role of [18 F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasia (NET) is a heterogeneous disease. While 68-Ga PET is considered the gold standard in GEP-NETs, the role of [18F]FDG PET/CT is not well established, particularly in well-differentiated G1 NETs.

Conference:

Presenting Author: Magi L

Authors: Magi L, Prosperi D, Lamberti G, Marasco M, Ambrosini V,

Keywords: Neuroendocrine tumor, disease aggressiveness, prognosis, management, PET,

#446 Comparative Expression Analysis of Somatostatin Receptor Subtypes in Human Neuroendocrine Tumors Using Two Sets of New Monoclonal Antibodies

Introduction: Expression of somatostatin receptor subtypes (sstr) is required for the successful use of somatostatin analogues (SSA) in the treatment of neuroendocrine tumors (NET). Reliable detection of sstr could improve the selection of SSA treatment. Rabbit and mouse monoclonal antibodies (mAbs) were recently developed independently in Jena and Basel.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Lambertini C, Nuciforo P, Schulz S, Schmid H,

Keywords: sstr, NET, sstr-specific mAb,

#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors

Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Lambertini C, Schmid H, Kaufmann M, Nuciforo P,

Keywords: Somatostatin receptor, neuroendocrine tumors, somatostatin receptor-specific monoclonal antibodies,

#19 Antitumor activity of Pasireotide (SOM230) alone and in combination with Everolimus (RAD001) in DU-145 human prostate cancer model

Introduction: Pasireotide (SOM230) is a novel multi-receptor ligand somatostatin analogue with high affinity for somatostatin receptor subtypes sst1,2,3 and sst5. Like octreotide, which binds primarily to sst2, it inhibits hypersecretion of hormones from patients with functional pituitary tumors and gastroenteropancreatic neuroendocrine (GEP/NET) tumors. In addition, tumor shrinkage has been observed with both compounds in patients with acromegaly, Cushing’s disease and GEP/NETs, but its tumor-reducing mechanism of action has so far not been revealed. In patients with breast and liver cancer, octreotide had little or no antitumor activity.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Herbert Schmid

Authors: Schmid H, Chiara L, Nuciforo P,

Keywords: Pasireotide, Everolimus, SOM230, RAD001, somatostatin, prostate, solid tumors,